返回
Clinuvel Pharmaceuticals Ltd（CLVLY）價格
CLVLY 股價走勢圖
CLVLY 收益
Clinuvel Pharmaceuticals Ltd
$8.39
0.59%
$0.05
收盤價：Jan 16, 16:00:00 GMT-5
$8.39
0%
$0
盤前：Jan 20, 06:52:44 GMT-5
關鍵數據
前收市價
$8.34
開盤價
$8.39
當日範圍
$8.39 - $8.39
52週區間
$6 - $9
交易量
20
平均成交量
2.6K
每股盈餘 (TTM)
0.47
股息收益率
--
市值
$421.1M
什麼是 CLVLY？
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The company has operations in Europe, Singapore, and the United States of America. The company develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.